-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Hematologic Toxicity of Immunotherapies

Program: Education Program
Hematology Disease Topics & Pathways:
Biological therapies, Therapies, Immunotherapy, Adverse Events
Saturday, December 9, 2023: 4:00 PM-5:15 PM
Room 6DE (San Diego Convention Center)
Chair:
Frederick L. Locke, MD, Moffitt Cancer Center
Disclosures:
Locke: Allogene: Consultancy, Other: Institutional ; Amgen: Consultancy; bluebird bio: Consultancy, Other: Institutional ; BMS/Celgene: Consultancy, Other: Institutional ; Calibr: Consultancy; Caribou: Consultancy; Iovance: Consultancy; Kite, a Gilead Company: Consultancy, Other: Institutional ; Janssen: Consultancy; Legend Biotech: Consultancy; Novartis: Consultancy, Other: Institutional ; Sana: Consultancy; Takeda: Consultancy; Wugen: Consultancy; Umoja: Consultancy; Cowen: Consultancy; GammaDelta Therapeutics: Consultancy; A2: Consultancy, Other: Travel support; ASH: Other; Imedex: Other; Daiichi Sankyo: Consultancy; Gerson Lehrman Group (GLG): Consultancy; Clinical Care Options Oncology: Other; Aptitude Health: Other; CERo Therapeutics: Other: Institutional; BioPharma Communications CARE Education: Other; Cellular Biomedicine Group: Consultancy; EcoR1: Consultancy; Emerging Therapy Solutions: Consultancy; Individual Patents: Patents & Royalties: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; National Cancer Institute: Other: Institutional ; Leukemia and Lymphoma Society: Other: Institutional ; Society for Immunotherapy of Cancer: Other: Institutional .
Hematologic Toxicity of CAR-T

Frederick L. Locke, MD

Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
Hematologic Toxicity of Checkpoint Inhibitors

Michael Kroll, MD

MD Anderson Cancer Ctr., Houston, TX
Hematologic Toxicity of Bispecific Antibody Therapies

Martin Hutchings, MD, PhD

University Hospital of Copenhagen, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
See more of: Education Program
<< Previous Session | Next Session >>